1. Introduction {#sec1}
===============

In the 1920s, Otto Warburg reported for the first time that while cells under normal conditions utilize glucose to derive 70% of required ATP through mitochondrial oxidative phosphorylation (OXPHOS), cancer cells metabolize glucose by glycolysis even in the presence of adequate oxygen supply [@bib1], [@bib2]. Since then, aerobic glycolysis has been regarded as a hallmark of cancer that provides bioenergetic, biosynthetic and redox balance advantages for cancer cells [@bib3].

Although Warburg\'s seminal studies resulted in a misinterpretation that irreversible inactivation of mitochondrial respiration is the primary and sole cause of aerobic glycolysis in cancer cells, later it was reported that impaired respiration is inadequate to explain the metabolic shift [@bib4]. The study of cancer cell glycolysis continues to surprise, revealing further associations between a metabolic switch in cancer cells, mutations in mitochondrial metabolic enzymes and altered mitochondrial function [@bib5], [@bib6]. In addition, discoveries that associate oncogene and tumor suppressor gene dysfunction with metabolic reprogramming suggest that both environmental and genetic factors underlie the metabolic heterogeneity of tumors [@bib7], [@bib8]. Moreover, in light of numerous microRNA-related studies, it is now important to consider the roles of these small non-coding RNAs in fine-tuning gene expression at different stages of tumourigenesis. Accumulating evidence supports the involvement of miRNAs in modulating cancer cell metabolism by directly and indirectly regulating genes associated with aerobic glycolysis [@bib9].

microRNAs (miRNAs) are small non-coding RNAs that canonically play a major role in post-transcriptional gene repression. Themselves the products of RNA polymerase II or III dependent transcription, primary (pri)-miRNA transcripts are 5′-7-methylguanosine capped, spliced and 3′-polyadenylated and may give rise to one or more mature miRNAs. Some miRNAs may also derive from processed intronic sequences [@bib10]. In the nucleus, pri-miRNAs are subjected to cleavage by Drosha releasing precursor (pre)-miRNA hairpin structures. Pre-miRNAs are then transported to the cytoplasm where cleavage by Dicer results in a 19--24 nucleotide double-stranded miRNA of which one strand, the mature miRNA, is transferred to the Argonaute (AGO) component of the RNA-induced silencing complex (RISC). AGO acts as a RISC effector protein modulating mRNA stability and translation [@bib11], [@bib12].

This review summarizes recent knowledge of the causes and consequences of the Warburg effect, paying particular attention to the contribution of miRNAs. It also aims to further discuss complex interactions between metabolic pathways and mitochondrial function, as well as oncogenic and tumor suppressor mutations. Finally, in view of recent findings, future approaches that can be exploited for therapeutic benefit are discussed.

2. Metabolic reprogramming {#sec2}
==========================

Proliferating cells and, indeed, cancer cells require constant cell division. In order to maintain this, there is an urgent need to provide a consistent energy source, macromolecular biosynthesis, and controlled redox status. Therefore, to optimize proliferation, growth, and survival, cancer cells redirect their metabolic pathways and alter the production and consumption of numerous metabolites [@bib13], [@bib14].

To support cancer cell proliferation, glycolysis provides the precursors for major macromolecules including the carbohydrates, proteins, lipids, and nucleic acids needed to produce a new cell. Therefore, aerobic glycolysis imbues cancer cells with ribose, amino acids and fatty acids [@bib15], [@bib16]. The upregulation of glycolysis is mostly due to the increased expression of enzymes and transporters involved in glucose uptake, lactate production, and lactate secretion. These proteins include glucose transporters (GLUT1-4), hexokinase 2 (HK2), glyceraldehyde-3- phosphate dehydrogenase (GAPDH), 6-phosphofructo-1-kinase (PFK1), aldolase (ALDO), triose-phosphate isomerase (TPI), phosphoglycerate kinase 1 (PGK1), phosphoglycerate mutase (PGM), enolase 1 (ENO1), pyruvate kinase (PKM2), lactate dehydrogenase (LDHA) and monocarboxylate transporters (MCTs).

There is substantial evidence regarding the importance of aberrant expression of oncomiRs and tumor suppressor miRNAs targeting key players in aerobic glycolysis to give proliferation, growth, and invasion advantages to cancer cells ([Figure 1](#fig1){ref-type="fig"}). Such changes in miRNA activity reflect a mechanism by which cancer cells bypass checkpoints that determine thresholds of biosynthetic enzyme activities.Figure 1miRNAs targeting glycolytic and mitochondrial enzymes.Figure 1

In addition to miRNAs directly targeting genes involved in cancer cell glycolysis, summarized in [Table 1](#tbl1){ref-type="table"}, several indirect mechanisms have been reported for miRNA-mediated regulation of glycolytic genes. Horie et al. [@bib17] showed that forced expression of miR-133 decreases *GLUT4* expression by directly targeting Kruppel-like factor 15 (*KLF15*) in cardiomyocytes. KLF15 is a transcription factor required for *GLUT4* transcription. Also, miR-155 was reported to upregulate HK2 through signal transducer and activator of transcription 3 (STAT3) activation, as well as through miR-143 repression by targeting CCAAT-enhancer-binding protein β (*C/EBPβ*). Moreover, miR-143 was found to target HK2 directly, linking inflammatory miR-155-related signaling with cancer-associated changes in metabolism [@bib18], [@bib19]. PKM is one of the rate limiting enzymes in glycolysis. While PKM1 expression was shown to be active in normal cells, cancer cells switch *PKM1* to the tumor-associated PKM2. Also, some miRNAs were reported to regulate polypyrimidine tract-binding protein 1 (PTB-1), which processes *PKM* transcripts and is involved in PKM1 to PKM2 conversion in tumor cells. These miRNAs, including miR-1, miR-124, miR-133b, miR-137 and miR-340 were shown to directly inhibit cancer cell proliferation and may also explain the repressed *PTB-1* expression associated with tumor progression *in vivo* [@bib20], [@bib21], [@bib22], [@bib23], [@bib24].Table 1Summary of miRNAs directly targeting glycolytic enzymes and transporters.Table 1GenemiRNAsDiseasesReferences***GLUT1***miR-495, miR-1291, miR-130b, miR-199a, miR-138, miR-150, miR-532, miR-301a, miR-19a/b, miR-22, miR-132, miR-218, miR-340, miR-541Renal Cell Carcinoma, Glioma, Breast Cancer, Prostate Cancer, Bladder Cancer, Oral Squamous Cell Carcinoma, Glioblastoma Multiforme[@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33]***GLUT2***miR-143--[@bib34]***GLUT3***miR-195, miR-106aBladder Cancer, Glioblastoma[@bib35], [@bib36]***GLUT4***miR-223, miR-93, miR-150, miR-192, miR-106bCardiomyocytes, Polycystic Ovary Syndrome, Diabetes Mellitus[@bib37], [@bib38], [@bib39], [@bib40]***HK1***miR-138Head and Neck Squamous Cell Carcinoma[@bib41]***HK2***miR-34a, miR-143, miR-125a/b, miR-497, miR-181b/c, miR-98, miR-4458, miR-199aColorectal Cancer, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Lung Cancer, Glioblastoma, Hepatocellular Carcinoma, Chronic Lymphocytic Leukemia, Primary keratinocytes, Osteocarcinoma, Prostate Cancer, Gastric Cancer[@bib18], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53]***GPI***miR-34a, miR-302b, miR-17, miR-200 familyColorectal Cancer, Primordial Germ Cells, Breast Cancer[@bib42], [@bib54], [@bib55]***PFK***miR-520, miR-320a, miR-106b, miR-26b, miR-206Hepatocellular Carcinoma, Lung Adenocarcinoma, Renal Cell Carcinoma, Osteosarcoma, Breast Cancer[@bib56], [@bib57], [@bib58], [@bib59], [@bib60], [@bib61]***ALDOA***miR-34c, miR-122, miR-15a, miR-16-1Emphysematous Lung, Hepatocellular Carcinoma, Leukemia, Lung Cancer[@bib62], [@bib63], [@bib64], [@bib65]***GAPDH***miR-644aProstate Cancer[@bib66]***TPI1***miR-15a, miR-16-1, miR-107, miR-195Leukemia, Renal Cell Carcinoma, Lung Cancer, Bladder Cancer[@bib63], [@bib65], [@bib67], [@bib68]***PGK1***miR-107, miR-29a, miR-1256, miR-17-92 clusterRenal Cell Carcinoma, Prostate Cancer, Lung Cancer, Pancreatic Cancer, Squamous Cell Lung Carcinoma[@bib67], [@bib69], [@bib70], [@bib71]***PGM***Let-7g, miR-29a, miR-33b, miR-21Primary Human Hepatocytes, Lung Cancer, Renal Cell Carcinoma[@bib60], [@bib70], [@bib72], [@bib73]***ENO1***miR-17-92 cluster, miR-29aLung Cancer[@bib70], [@bib71]***PKM2***miR-34a, miR-122, miR-133a/b, miR-326, miR-99a, miR-128Colorectal Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Tongue, Glioblastoma, Type 2 Diabetes, Prostate Cancer[@bib42], [@bib74], [@bib75], [@bib76], [@bib77]***LDHA***miR-375, miR-24, miR-23a, miR-210, miR-30a, miR-34a/c, miR-374a, miR-383, miR-4524a/b, miR-369, miR-410, miR-590Maxillary Sinus Squamous Cell Carcinoma, Acute Myocardial Ischemia, Breast Cancer, Colorectal Cancer, Hypoxia-Induced Cardiomyocytes Dysfunction, Ovarian Cancer, Cervical Cancer, Gestational Diabetes Mellitus, Type2 Diabetes[@bib78], [@bib79], [@bib80], [@bib81], [@bib82], [@bib83], [@bib84], [@bib85], [@bib86], [@bib87], [@bib88]***MCTs***miR-29a/b, miR-124, miR-376a-5p, miR-495Pancreatic β Cells, Medulloblastomas, Type2 Diabetes[@bib89], [@bib90], [@bib91]

Although several decades have passed since the first report on cancer metabolism, with many studies since, a definitive mechanism underpinning the Warburg metabolic shift has remained obscure. Moreover, how individually disrupted metabolic pathways converge to coordinate a global metabolic shift and facilitate the tumor phenotype remains to be fully elucidated.

3. Inter-connection between aerobic glycolysis and mitochondria {#sec3}
===============================================================

Whilst glycolysis accounts for the generation of almost two thirds of the ATP required for tumor cells, in most cancer cells mitochondria are still functional and generate the remaining energy requirements [@bib92]. Mitochondria also contribute to pivotal roles in controlling anaplerotic and cataplerotic pathways within cancer cells. Indeed, several roles for mitochondria in carcinogenesis, other than ATP production for cellular demands, have been established [@bib93]. As a result, functions including hypoxia resistance, apoptosis escape, reactive oxygen species (ROS) control, and bio-synthetic contributions are attributed to mitochondria. Mutations in mitochondrial TCA cycle genes, encoded by nuclear DNA, were found in various types of cancers. Mutational inactivation of these enzymes contributed to a metabolic shift through direct adaptation to decreased OXPHOS or, alternatively, by epigenetic modification caused by cytosolic and mitochondrial accumulation of oncometabolites such as 2-hydroxyglutarate (2HG) [@bib94], [@bib95], [@bib96], [@bib97], [@bib98].

Studies of miRNA localization from nucleus to mitochondria have led to the discovery of mitochondria-related miRNAs (mitomiRs). A considerable body of literature demonstrated the miRNA contributions to every aspect of mitochondrial metabolism, respiration, and dynamics [@bib99]. Additionally, ROS generated within mitochondria were found to be strictly regulated by several miRNAs (reviewed in [@bib100]). miRNAs that regulate tricarboxylic acid (TCA) cycle transcripts include miR-183, miR-210 and miR-734a, which target isocitrate dehydrogenase (*IDH*), succinate dehydrogenase (*SDH*), and malate dehydrogenase (*MDH*), respectively [@bib101], [@bib102], [@bib103] ([Figure 1](#fig1){ref-type="fig"}). Moreover, several electron transport chain components are reportedly regulated by miRNAs. For instance, miR-338 and miR-181c downregulate cytochrome c oxidase complex COX4 and COX1, respectively. Hypoxically regulated miR-210 represses iron-sulfur cluster scaffold (*ISCU*) and *COX10* translation [@bib104], [@bib105], [@bib106]. Glutaminase (GLS) is a rate-limiting enzyme in glutamine metabolism which converts glutamine to glutamate. An increasing number of reports revealed cooperation of c-Myc and p53 with several miRNAs such as miR-23a/b, miR-125b, miR-30 and miR-504 in modulating GLS activity [@bib107]. Based on these reports, it is clear that miRNAs target both nuclear mRNAs and mitochondrial mRNAs. Moreover, the Crabtree effect, originally identified in fermenting yeast, enables some cancer cells to switch between glycolysis and OXPHOS in spite of functional mitochondria and also challenges the "purely glycolytic cancer cell" paradigm. The Crabtree effect is considered to be a short-term and reversible mechanism and an adaptive response of mitochondria to the heterogeneous microenvironment of cancer cells [@bib108]. Hence, there is still a need to fully determine whether changes in mitochondrial functionality, mediated by several miRNAs, contribute to cellular transformation. Otherwise it may be considered a secondary phenomenon, which arises from changes in cell glycolysis and/or other signaling pathways also regulated by miRNAs.

4. Hypoxia and glycolysis {#sec4}
=========================

Hypoxia is a common feature in proliferating solid tumors. In normal cells, hypoxia leads to cellular adaptation, or p53-dependent apoptosis and cell death. However, cancer cells acquire mutations in p53 and other genes, along with changes in their metabolic pathways in order to survive and even proliferate under hypoxic stress. A key mediator of responses to hypoxia is hypoxia-inducible factor-1 (HIF-1), a transcription factor that plays a pivotal role in responding to decreased oxygen levels, initiating hypoxia-related processes such as OXPHOS repression and induced glycolysis [@bib109].

Although prolyl-4-hydroxylase (PHD) and factor inhibiting HIF-1 (FIH-1; also known as HIF1AN) dependent regulation of HIF-1 is primarily thought to be the sole mechanism of HIF-1 regulation [@bib110] it is now clear that hypoxia influences miRNA biogenesis and these miRNAs can regulate *HIF-1α* and *HIF-1β* expression [@bib111]. HIF-1α is also regulated at the DNA, RNA, protein and DNA binding levels [@bib112]. Translational regulation of HIF-1α could also be a consequence of activating the mechanistic target of rapamycin (mTOR) signaling pathway in cancer cells. Many miRNAs, such as miR-99a, were shown to repress *HIF-1α* expression by targeting mTOR [@bib76]. The abnormal activation of HIF-1 under normoxia could alternatively be a result of changes in cancer-associated genes. Such tumourigenic mutations include loss of function in tumor suppressors such as P53, phosphatase and tensin homolog (PTEN) [@bib113], Von Hippel-Lindau (VHL) [@bib114], LKB1 [@bib115], promyelocytic leukemia protein (PML) [@bib116], and tuberous sclerosis proteins (TSC1/TSC2) [@bib117] along with mutational activation of oncogenes such as *Ras* [@bib118], *V-Src* [@bib119], phosphoinositide 3-kinase (*PI3K*) [@bib120], and human epidermal growth factor receptor 2 (*Her2/Neu*) [@bib121]. PKM2 was also reported to enhance *HIF-1* transcription, through binding to its promoter, and promote HIF-1 stabilization by inhibiting PHD interactions [@bib122]. Mitochondria also act as both targets and effectors of HIF-1 activation [@bib100]. To adapt to a hypoxic microenvironment and acquire lethal cancer characteristics, HIF-1 activation leads to a range of physiological responses [@bib123]. At the transcriptional level, HIF-1α activates a variety of genes following translocation into the nucleus, dimerization with HIF-1β and binding to hypoxia response elements (HREs) upstream of target genes. Besides HRE-dependent responses, HIF-1α interacts with other signal transduction pathways including Notch [@bib124], Wnt [@bib125] and c-Myc [@bib126].

Activated HIF-1 is directly and indirectly associated with increased expression of virtually all glycolytic transporters and enzymes [@bib123]. Moreover, HIF-1 affects mitochondria through various mechanisms and stimulates glycolysis indirectly by supressing mitochondrial oxidative metabolism, which enables HIF-1 to function as a switch between glycolysis and OXPHOS [@bib127]. HIF-1 represses mitochondrial pyruvate dehydrogenase (PDH) activity [@bib109], which is a gate-keeping enzyme feeding the TCA cycle by converting pyruvate to acetyl-CoA. HIF-1 suppresses PDH expression by actively upregulating pyruvate dehydrogenase kinase (PDK1), a PDH suppressor [@bib128]. By such regulation, pyruvate is converted to lactate, cytosolic NADH is re-oxidized and glycolysis is continued. As a consequence, PDH suppression by activated HIF-1 protects cells from increased ROS generated within mitochondria [@bib129]. In addition, HIF-1 regulates mitochondrial function in response to oxygen by mediating a subunit switch in COX4. HIF-1 induces COX4I2 subunit expression under hypoxic conditions, while the normoxic COX4I1 subunit is downregulated through HIF-1-mediated activation of LON, a mitochondrial protease. This subunit switch optimizes the efficiency of respiration in response to hypoxia by influencing H~2~O~2~ levels in an oxygen-dependant manner [@bib127]. Zhao et al. [@bib130] showed that HIF-1α upregulates TKT and TKTL2, two transketolase enzymes of the pentose phosphate pathway, to elevate the ribose production required for nucleic acid anabolic pathways.

Thus far, no mutations within the *HIF-1* genes have been associated with its activation or related regulation of glucose metabolism. However, aberrant HIF1 activity has proved to be important in the initiation and maintenance of some tumors [@bib112].

Hypoxia is a significant mediator of miRNA biosynthesis, at both the transcriptional and post-transcriptional levels [@bib131]. A recently identified subset of miRNAs are known as "hypoxia regulated miRNAs" (also termed hypoxiamiRs or HRMs). Hypoxia regulates hypoxiamiRs in either a HIF-1 dependent or independent manner [@bib132]. First reported by Kulshreshtha et al. [@bib111], hypoxia is capable of upregulating miRNA expression ([Table 2](#tbl2){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}). Among these hypoxia-inducible miRNAs, miR-210 and miR-26 were found to have dynamic recruitment of HIF-1 to their promoters. Upon activation, HIF-1α translocates to the nucleus and targets HREs of downstream genes, including miRNA encoding genes. Interestingly, hypoxia is also associated with miRNA downregulation. In that regard, the miR-17--92 cluster was downregulated by hypoxia in p53 wild type cells [@bib133]. Similarly, Lei et al. [@bib134] reported miR-20b upregulation in HIF1-knockdown cells. Other hypoxia-suppressed miRNAs are listed in [Table 2](#tbl2){ref-type="table"}. Nevertheless, contrasting reports, with miRNAs such as miR-26 and miR-19, demonstrate that hypoxia-dependent regulation of miRNAs is cell type and microenvironment dependent [@bib111], [@bib135]. Among downregulated hypoxiamiRs, HIF-1 was shown to downregulate miR-17 and miR-199a [@bib136], [@bib137]. HIF-1 also regulates miRNA expression indirectly by mediating the expression of other transcription factors, examples being activation of miR-10b by HIF-1-dependent *TWIST1* expression and regulation of miR-20a/b through vascular endothelial growth factor A (VEGFA) targeting by HIF-1 [@bib138], [@bib139]. Beside miRNAs directly regulated by hypoxia, it is evident that hypoxia is post-transcriptionally involved in the regulation of hypoxiamiR biogenesis, processing and function in both a HIF-dependent and independent manner. It was shown that hypoxia accelerates Ago2 assembly to RISC and its translocation to stress granules by upregulating Ago2 prolyl-hydroxylation and increasing its endonuclease activity [@bib140]. Moreover, HIF-1 regulates expression of the prolyl 4-hydroxylase, alpha polypeptide I (P4HA1) by regulating miR-124 expression [@bib141]. In fact, stress granule formation increased in a hypoxia-dependent manner. Nonetheless, ADP-ribosylaton of Ago2 in response to oxidative stress is another mechanism that eventually leads to relief of miRNA-mediated repression. Interestingly, it was reported that some miRNA maturation that is not dependent on Dicer activity [@bib142], might be processed by the endonuclease activity of Ago2, the levels of which are induced by hypoxia. Accordingly, Dicer was found to be downregulated by hypoxia, while miR-451 was upregulated [@bib143], [@bib144].Table 2Summary of associations between miRNAs and hypoxia.Table 2miRNADisease/cell lineRegulation of HIF/mechanismRegulation of miRNA by HypoxiaReferencesmiR-17-92 clusterLung Cancer, Cervical Adenocarcinoma, Inflammation, Colon Cancer, Brest Cancer, HepatocarcinomaDownregulation/targeting *HIF-1α* and *HIF-2*Downregulation[@bib71], [@bib134], [@bib136], [@bib159], [@bib160], [@bib163], [@bib166]miR-15bHemophilia, Nasopharyngeal CarcinomaDownregulation/targeting *HIF-2*Downregulation[@bib166], [@bib167]miR-16Nasopharyngeal CarcinomaNADownregulation[@bib166]miR-19aOral Squamous Cell Carcinoma, Human Atherosclerotic LesionsNADownregulation/Upregulation[@bib135], [@bib168]miR-20a/bNasopharyngeal Carcinoma, Lung CancerDownregulation/targeting *HIF-1α* and *HIF-2α*Downregulation[@bib71], [@bib166]miR-21Breast Cancer, Prostate CancerUpregulationUpregulation[@bib111], [@bib150], [@bib169]miR-22Clear Cell Renal Cell Carcinoma, Colorectal Cancer, Heart muscle, Oral Squamous Cell CarcinomaDownregulation/targeting *HIF-1α*Upregulated/Downregulated[@bib132], [@bib135], [@bib170], [@bib171]miR-23a/bColorectal Cancer, Breast CancerNAUpregulated[@bib111], [@bib172]miR-24Colorectal Cancer, Breast CancerNAUpregulated[@bib172]miR-26a/bNasopharyngeal Carcinoma, Colorectal Cancer, Breast CancerNAUpregulated/Downregulated[@bib166], [@bib172]miR-27a/bHeart Muscle, Colorectal Cancer, Breast CancerNAUpregulated[@bib132], [@bib172]miR-30 b/d/eOral Squamous Cell Carcinoma, Colorectal Cancer, Breast Cancer, Nasopharyngeal CarcinomaNADownregulation/Upregulated[@bib135], [@bib166]miR-29bOral Squamous Cell CarcinomaNADownregulated[@bib135], [@bib172]miR-31Colorectal Cancer, Human Corneal Epithelial Keratinocytes, Oral Squamous Cell CarcinomaUpregulation/targeting *FIH1*Upregulated[@bib135], [@bib145], [@bib147], [@bib173], [@bib174]miR-33aMelanomaDownregulation/targeting *HIF-1α*NA[@bib175]miR-93Colorectal Cancer, Breast CancerNAUpregulation[@bib111]miR-99aType 2 DiabetesDownregulation/targeting *HIF-1α*NA[@bib76]miR-101Oral Squamous Cell CarcinomaNADownregulation[@bib135]miR-103Colorectal Cancer, Breast CancerNAUpregulated[@bib111]miR-106bColorectal Cancer, Breast CancerNAUpregulated[@bib111]miR-107Ischemic Heart Disease, Colorectal Cancer, Colorectal Cancer, Breast CancerDownregulation/targeting *HIF-1β*Upregulation[@bib111], [@bib151], [@bib152]miR-122aOral Squamous Cell CarcinomaNADownregulation[@bib135]miR-125bColorectal Cancer, Breast CancerNAUpregulated[@bib111]miR-128Prostate CancerDownregulation/targeting *HIF-1α*NA[@bib77]miR-135bProstate Cancer, Breast CancerUpregulation/targeting FIH-1NA[@bib142], [@bib176]miR-138Clear Cell Renal Cell Carcinoma, Ovarian CancerDownregulation/targeting *HIF-1α*NA[@bib177], [@bib178]miR-141Oral Squamous Cell CarcinomaNADownregulation[@bib111]miR-155Cervical Adenocarcinoma, Nasopharyngeal CarcinomaDownregulation/targeting *HIF-1α*Upregulation[@bib159], [@bib166]miR-181a/b/cColorectal Cancer, Breast Cancer, Nasopharyngeal Carcinoma, Heart MuscleNAUpregulated/Downregulated[@bib111], [@bib132], [@bib166]miR-184GliomaUpregulation/targeting FIH-1NA[@bib146]miR-186Oral Squamous Cell Carcinoma, Gastric CancerDownregulation/targeting *HIF-1α*Downregulation[@bib135], [@bib179]miR-192Colorectal Cancer, Breast CancerNAUpregulated[@bib111]miR-195Hypoxic Chondrocytes, Colorectal Cancer, Breast CancerDownregulation/targeting *HIF-1α*Upregulation[@bib111], [@bib180]miR-197Oral Squamous Cell CarcinomaNADownregulation[@bib135]miR-199a/bOvarian Cancer, Sickle Cell Disease, Lung Cancer exposed to arsenic, Heart muscleDownregulation/targeting *HIF-1α* and *HIF-2α*Downregulation[@bib132], [@bib137], [@bib181], [@bib182]miR-204Pulmonary Arterial HypertensionDownregulation/targeting *HIF-1α*NA[@bib183]miR-206Pulmonary Arterial HypertensionDownregulation/targeting *HIF-1α*NA[@bib149]miR-210Cervical Cancer, Head and Neck Paragangliomas, Hypotriploid Human Kidney Cell Line, Ischemia, Breast Cancer, Nasopharyngeal Carcinoma, Oral Squamous Cell Carcinoma, Heart Muscle, Colorectal Cancer, Breast CancerNAUpregulation[@bib111], [@bib132], [@bib135], [@bib154], [@bib166], [@bib184], [@bib185], [@bib186]miR-213Colorectal Cancer, Breast CancerNAUpregulation[@bib111]miR-361Umbilical Vein Endothelial Cells (HUVEC)Downregulation/targeting *HIF-1α*Downregulation[@bib187]miR-374Oral Squamous Cell Carcinoma, Breast CancerUpregulation/targeting *TXNIP*Downregulation[@bib135], [@bib188]miR-422bOral Squamous Cell CarcinomaNADownregulation[@bib135]miR-424Ovarian Cancer, Oral Squamous Cell CarcinomaUpregulation/targeting *CUL2*Downregulation[@bib134], [@bib135], [@bib156]miR-429Human Endothelial CellsDownregulation/targeting *HIF-1α*Upregulation[@bib165]miR-494Lung CancerNANA[@bib157]miR-519cHepatic CancerDownregulation/targeting *HIF-1α*NA[@bib189]miR-565Oral Squamous Cell CarcinomaNADownregulation[@bib135]Figure 2**Interconnections between the drivers and suppressors of glycolysis, and the role of miRNAs in these networks.** Protein--protein interactions identified using String V10.0. Solid blue lines indicate protein activation while solid red lines indicate protein inhibition. Dotted blue and red lines represent transcription factor-mediated activation or inhibition of the miRNAs, respectively. miRNAs in pink boxes repress gene expression, while those in orange and blue boxes indicate miRNAs that are inhibited or activated by the transcription factors, respectively. Specific miRNAs present in both the pink boxes and either the orange or blue boxes, may represent feedback loops in particular cellular contexts.Figure 2

*HIF-1α* may be directly targeted by miRNAs in various diseases, including cancer ([Table 2](#tbl2){ref-type="table"}). Besides direct translational repression, some miRNAs inhibit other factors that modulate HIF-1 expression and stability. As FIH-1 inhibits the transcriptional activation of *HIF-1α*; miRNAs that suppress FIH-1, such as miR-31, miR-135b, and miR-184, result in *HIF-1* activation [@bib142], [@bib145], [@bib146]. FIH-1 was also shown to regulate cell metabolism through reducing glycogen and attenuating AKT signaling [@bib147]. miR-92-1 supresses HIF-1 degradation by targeting *pVHL* [@bib148]. miR-206 targets the HIF-1/FHL-1 pathway on pulmonary artery smooth muscle cells to promote hypertension [@bib149]. Increased expression of miR-21 was shown to increase *HIF-1α* and *VEGF* expression in prostate cancer possibly through a PTEN-dependant pathway [@bib150]. miR-107 downregulates mRNA and protein levels of *HIF-1β* in endothelial progenitor cells while overexpression of *HIF-1β* also blocks the effects of miR-107 [@bib151], [@bib152]. miR-185 targets *HIF-2a* transcripts and, thus, indirectly moderates HIF-1 expression and stability [@bib153].

Feedback loops have been reported in the miRNA regulation of *HIF-1*. miR-210 forms a positive feedback loop with HIF-1 where hypoxia-induced miR-210 further induces HIF-1α protein stability [@bib154]. Kelly et al. [@bib154] showed that miR-210 targets glycerol-3-phosphate dehydrogenase 1 like (*GPD1L*), a HIF-1 regulator, and overexpression of miR-210 results in decreased HIF-1 proline hydroxylation and increased accumulation during hypoxia. What\'s more, HIF-1 directly induces miR-210 expression, which then causes synthesis of cytochrome c oxidase 2/1 (SCO2/1) protein activation and enhanced TCA cycle function [@bib155]. Hypoxia was shown to induce C/EBP levels, which, in turn, increase PU1 activation and binding to the miR-424 promoter to induce its expression. Upregulated miR-424 inhibits cullin 2 (CUL2) and leads to HIF-1 stabilization and nuclear translocation [@bib156]. Overexpression of miR-494 and miR-21 significantly increases Akt phosphorylation and subsequently induces HIF-1 activity [@bib150], [@bib157]. Recent evidence that the activities of non-coding RNAs, including oncogenic miR-21, can be manipulated by small molecules suggests that such processes may be druggable [@bib158].

As a predominant oncomiR, the miR-17--92 cluster has been heavily investigated for its association with hypoxia. Bertozzi et al. [@bib159] showed that miR-17-5p reduced HIF-1α at low camptothecin exposure. miR-17 and miR-20a also target the 3′UTR of *HIF-1* and *HIF-2* in primary human macrophages [@bib160]. All members of this cluster were shown to directly target HIF-1 in lung cancer [@bib71]. miR-17 and miR-20a were downregulated by HIF-1 through a transcriptional and HIF-1β-independent manner and by downregulating *c-Myc* expression [@bib136]. miR-20a is a hypoxia-responsive miRNA that targets *HIF-1* in breast cancer, lung adenocarcinoma, colorectal cancer, and endometriotic stromal cells [@bib71], [@bib138], [@bib160], [@bib161], [@bib162]. In the paralogous miR-106a∼363 cluster, miR-20b is known to target HIF-1 in hepatocellular carcinoma (HCC) and breast cancer cells [@bib163], [@bib164]. Also, chromatin immunoprecipitation analyses revealed that miR-20b prevents HIF-1 binding to the *VEGF* promoter and, thus, modulates *VEGFA* expression [@bib163].

Aberrant expression of miRNAs, which can result from hypoxia encountered during tumor progression, may play a critical role in HIF-1 regulation and altered downstream effects ([Figure 2](#fig2){ref-type="fig"}). Interestingly, some miRNAs that target HIF-1 were also reported to be modulated by hypoxia in both a HIF-dependent and independent manner. However, some anomalies regarding hypoxiamiRs and miRNAs that regulate HIF-1 still exist. For instance, Bartoszewska et al. [@bib165] showed that *HIF-1* is a direct target of miR-429 in HUVEC cells and is induced during hypoxia. However, Sun et al. [@bib157] showed that overexpression of miR-429 increases *HIF-1α* expression, under both hypoxia and normoxia, and couldn\'t find a miR-429 target sequence in the 3′UTR of *HIF-1α* in liver cells. These inconsistencies likely depend on cellular context and experimental conditions. Moreover, as HIF is mainly post-translationally regulated, miRNA activity may be largely redundant in some systems. [Table 2](#tbl2){ref-type="table"} summarizes the associations between hypoxia and miRNAs in different cancers. It has been proposed [@bib92] that the observed Warburg effect is entirely attributable to the *in vivo* tumor hypoxia and is, in fact, a manifestation of the Pasteur Effect.

5. Metabolic consequences of miRNA associations with driver mutations and transformation {#sec5}
========================================================================================

While oncoproteins and tumor suppressor proteins are well-known for their roles in regulating cellular processes such as cell proliferation, they are also capable of affecting cancer cell metabolism. Activation of certain oncogenic signals is important for stimulating glycolysis. Various mutations in different oncogenes and tumor suppressors show that cancer cells alter metabolism to adapt to their microenvironment [@bib190]. These fundamental genes include oncogenes such as *KRAS*, *MYC*, *AKT*, and *MTOR,* along with their inhibitors (*PTEN* and *TSC1/2*) and activator (*EGFR*). They also include tumor suppressor genes such as *TP53*, along with its negative regulator murine double mutant 2 (*MDM2*) and metabolic effector TP53-induced glycolysis and apoptosis regulator (*TIGAR*). Sirtuins are further regulatory molecules that can act both as oncogenes and tumor suppressors and will be discussed later. Accumulating evidence highlights the association of miRNAs with oncogenes and tumor suppressors. Some cancer associated genes, such as *HIF1*, *MYC* and *TP53,* regulate both the expression and functions of some miRNAs and are regulated by miRNAs. [Table 5](#tbl5){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"} summarize recent findings on miRNA-mediated regulation of oncogenes and tumor suppressors.

5.1. KRAS proto-oncogene {#sec5.1}
------------------------

The *KRAS* oncogene features as an early mutation in up to 45% of colorectal tumors, notable because it can drive many hallmarks of cancer [@bib191]. *KRAS*-mediated transformation is linked with mitochondrial respiratory dysfunction and elevated NADPH oxidase (NOX)-mediated ROS generation [@bib192], [@bib193]. Wang et al. [@bib194] postulated that oncogenic KRAS influences complex I activity in the electron transport chain, most likely by downregulating complex I assembly factor protein (NDUFAF1) and, as a consequence, induces mitochondrial dysfunction. However, additional oncogenic signals and/or loss of tumor suppressors, including dysregulated miRNAs, are required for tumourigenesis.

Unsurprisingly, *KRAS* is a target of multiple miRNAs, including let-7, miR-96, miR-134 and miR-143 (Summarized in [Table 5](#tbl5){ref-type="table"}). These miRNAs affect cancer cell metabolism, cell cycle arrest, apoptosis, cell migration and invasion, especially by modulating RAS/MAPK signaling ([Figure 2](#fig2){ref-type="fig"})

*KRAS* is frequently mutated in human neoplasia including pancreatic, colorectal and lung cancer. The oncogenic *KRAS*^*G12V*^ variant, which leads to higher KRAS activity, was reported to be the most frequent mutation. However, despite low *KRAS* mutation frequency in glioblastoma and breast cancer cells, activation of the wild-type KRAS pathway is common in these cancers. Also, sequence variants in the *KRAS* 3′UTR (rs712) were found in gastric cancer, colorectal cancer, papillary thyroid cancer, breast cancer, and non-small cell lung cancer, which disrupt let-7 binding site and subsequent miRNA-mediated downregulation [@bib195], [@bib196], [@bib197], [@bib198], [@bib199].

The expression of some miRNAs such as let-7, miR-126, miR-200c, miR-193b, and miR-4689 was found to be lower in *KRAS* mutant cells, as compared to tumors expressing wild-type *KRAS* [@bib199], [@bib200], [@bib201], [@bib202], [@bib203], confirming the context dependent activity of miRNAs, even in regulating *KRAS* itself. Kopp et al. [@bib200] reported that in breast cancer cells harboring the *KRAS*^*G13D*^ mutation, miR-200c targets *KRAS* transcripts and inhibits proliferation and cell cycle progression, while in *KRAS* wild type cells miR-200c affects proliferation through other targets. Despite different miR-126 expression levels in *KRAS* mutant and wild type colon cancer cells, Hara et al. [@bib201] showed that over-expression of miR-126 does not alter *KRAS* expression and function. In contrast, Jiao et al. [@bib204] showed *KRAS* regulation by miR-126 in pancreatic cancer. Such variations suggest that the activity of some miRNAs is subjected to changes through both transcriptional and post-transcriptional processes during tumourigenesis. Examples are erythropoietin-producing hepatoma receptor A1 (EphA1) upregulating let-7 in multiple myeloma [@bib205], EVI1 suppressing miR-96 in pancreatic ductal adenocarcinoma [@bib206], KLF4 downregulating miR-134 in glioblastoma [@bib207] and MYC associated factor X (MAX) inhibiting miR-193a in breast cancer [@bib208]. Therefore, coordinated suppression of miRNAs, as is found in various cancers, would not only influence oncogenic *KRAS* activity but may also influence other genes involved in KRAS-related signaling to cooperatively initiate tumourigenesis, including genes in metabolic pathways.

5.2. MYC proto-oncogene {#sec5.2}
-----------------------

Overexpression of the *c-MYC* proto-oncoprotein plays pivotal roles in sustaining the transformed phenotype of most cancer cells [@bib209]. The discovery that LDHA is among 20 putative targets of c-MYC provided evidence that c-MYC directly regulates glycolysis. Since then, other glycolytic genes including *GLUT*s, *GAPDH*, *PGK*, *HK2*, *ENO1*, *PGM*, *PKM2*, and *MCT*s are also reportedly induced by c-MYC [@bib210].

Along with its role in glycolysis, c-MYC was found to regulate mitochondrial biogenesis, respiration, and function [@bib211]. Upregulation of some nuclear genes that encode proteins for mitochondrial function, mitochondrial DNA replication and transcription of mitochondrial DNA are known to be direct consequences of *c-MYC* overexpression [@bib212]. c-MYC also contributes to mitochondrial biogenesis and gives rise to the synthesis of acetyl-CoA and fatty acid biosynthesis required for cancer cell proliferation. In parallel, c-MYC upregulates the glutamine catabolism required for biosynthetic processes by inducing GLS and the glutamine transporters, ASCT2 and SLC7A25 [@bib213], [@bib214]. Overall, while c-MYC enhances glycolysis and consequently depletes pyruvate required for mitochondrial OXPHOS, it also confers the ability for cancer cells to utilize non-glucose substrates and maintain mitochondrial respiration to support cancer cell proliferation and progression.

c-MYC cooperates with HIF-1, or acts independently, to regulate glycolysis and OXPHOS [@bib215]. In normal cells, MYC enhances glycolytic flux to OXPHOS. However, in cancer cells, c-MYC cooperates with HIF-1 and PKM2 to upregulate glycolysis and provide adequate metabolic intermediates for biomass synthesis [@bib216]. While upregulation of HIF-1-mediated glycolysis was observed under hypoxic conditions, c-MYC regulates glycolytic genes independently under normal oxygen tension. In addition, while HIF-1 upregulates PDK1 under hypoxia, c-MYC cooperates with HIF-1 to further upregulate *PDK1* and, thus, amplifies the hypoxic response. Therefore, under normoxia, c-MYC enhances glycolysis, but it cooperates with HIF-1 to upregulate *PDK1* and reduce mitochondrial respiration under hypoxic conditions [@bib217]. Intriguingly, elevated ENO1 was shown to form a negative feedback loop with activated c-MYC. c-MYC-induced ENO1 increases the expression of MBP1, a transcription factor, and suppresses *c-MYC* expression [@bib218].

c-MYC both regulates miRNA expression and is, in turn, controlled by them ([Table 3](#tbl3){ref-type="table"}, [Table 5](#tbl5){ref-type="table"}). Several miRNAs have been shown to modulate *c-MYC* expression by different mechanisms ([Figure 2](#fig2){ref-type="fig"}). Let-7a, miR-22, miR-33b, miR-34a, miR-130a, miR-145, and miR-155 were found to suppress *c-MYC* after binding with canonical target sequences in the *c-MYC* 3′UTR [@bib219], [@bib220], [@bib221], [@bib222], [@bib223], [@bib224], [@bib225], [@bib226]. miR-24 binds to a seedless, but highly complementary, sequence while miR-18-5p and miR-774 bind to the protein coding region of *c-MYC* mRNA [@bib221], [@bib227], [@bib228]. Some other miRNAs, such as miR-363-3p act more indirectly. In HCC, miR-363-3p destabilizes c-MYC through targeting USP28, a ubiquitin protease of MYC, and promoting the degradation of pre-existing c-MYC protein [@bib229]. Several reports indicate a coordinated and reciprocal relationship between c-MYC and miRNA expression levels. For instance, Liao et al. [@bib228] showed a negative feedback and auto-regulatory role for c-MYC levels, as monitored by miR-185-3p. They confirmed that miR-185-3p is a genuine transcriptional target of c-MYC but also that miR-185-3p inhibits *c-MYC* translation by targeting the coding region of *c-MYC* transcripts.Table 3Summary of miRNAs regulated by the transcription factor MYC.Table 3miRNARegulationDisease/cellsReferencesmiR-2bUpregulationDrosophila S2 Cells[@bib242]miR-277UpregulationDrosophila S2 Cells[@bib242]miR-92UpregulationNeuroblastoma, Burkitt Lymphoma[@bib233], [@bib243]miR-106aUpregulationNeuroblastoma, Burkitt Lymphoma[@bib233], [@bib243]Let-7a/cUp/DownregulationNeuroblastoma, Burkitt Lymphoma, Breast Cancer, Prostate cancer[@bib234], [@bib235], [@bib243], [@bib244]miR-17UpregulationNeuroblastoma, Burkitt Lymphoma[@bib233], [@bib243]miR-93UpregulationNeuroblastoma[@bib243]miR-99UpregulationNeuroblastoma[@bib243]miR-221UpregulationNeuroblastoma[@bib243]miR-18UpregulationBurkitt Lymphoma[@bib233]miR-19UpregulationBurkitt Lymphoma[@bib233]miR-20UpregulationBurkitt Lymphoma[@bib233]miR-15aDownregulationLymphoma[@bib245]miR-16DownregulationLymphoma[@bib245]miR-22DownregulationLymphoma[@bib245]miR-23a/bDownregulationLymphoma, Prostate Cancer[@bib107]miR-26a/bDownregulationLymphoma, Burkitt Lymphoma, Prostate Cancer[@bib245], [@bib246], [@bib247]miR-29DownregulationLymphoma, lung Adenocarcinoma[@bib245], [@bib248]miR-34DownregulationLymphoma[@bib245]miR-146aDownregulationLymphoma[@bib245]miR-150DownregulationLymphoma[@bib245]miR-195Downregulationlymphoma[@bib245]miR-141UpregulationEmbryonic Stem Cells, Nasopharyngeal Carcinoma[@bib249], [@bib250]miR-200UpregulationEmbryonic Stem Cells[@bib249]miR-429UpregulationEmbryonic Stem Cells[@bib249]miR-9UpregulationBreast Cancer[@bib251], [@bib252]miR-185UpregulationNon-small Cell Lung Cancer[@bib228]miR-122DownregulationHepatocellular Carcinoma[@bib230], [@bib231], [@bib232]

c-MYC activates or represses a variety of genes, including miRNA genes, mainly through interactions with different complexes and proteins. c-MYC supresses *MIR122* gene transcription in liver tumors through association with a conserved promoter region upstream of the *MIR122* gene. It also downregulates hepatocyte nuclear factor 3-beta (HNF3β), which normally activates miR-122 and enhances its stability [@bib230], [@bib231].

miR-122 was reported to supress *c-MYC* expression indirectly by targeting *E2F1* and *TFDP2* (E2F dimerization partner 2) mRNA [@bib232]. In addition, feedback regulation was reported for miR-17-5p/c-MYC/E2F in some cancers, including breast and prostate [@bib233]. Nadiminty et al. [@bib234] reported a LIN28/let-7/c-MYC loop that plays an important role in some cancers. Relief of c-MYC repression occurs when LIN28, a highly conserved RNA-binding factor, binds let-7 precursors and inhibits miRNA maturation [@bib235]. There is a direct relationship between c-MYC, its dimerization partner, MAX, and the expression of some miRNAs such as let-7a and miR-22 [@bib225], [@bib236]. c-MYC can also transcriptionally activate some miRNAs, including the miR-17-92 cluster, through interaction with MAX protein at the polycistronic promoter region [@bib233], [@bib237]. Ting et al. [@bib225] showed that increased miR-22 limits the amount of MAX protein available for c-MYC binding by directly targeting it and, therefore, affects the expression of downstream targets of the c-MYC/MAX complex. In contrast, interaction of c-MYC with MIZ-1 represses expression of some c-MYC target genes through displacement of p300 co-activator protein [@bib238]. There is also a miRNA/c-MYC negative feedback loop in HCC with miR-148a-5p directly targeting *c-MYC* and, as previously mentioned, miR-363-3p indirectly destabilizing c-MYC by targeting ubiquitin specific peptidase 28 (USP28) [@bib229]. Other miRNAs that are repressed transcriptionally and post-transcriptionally by c-MYC are summarized in [Table 3](#tbl3){ref-type="table"}.

The activation of c-MYC alone is unable to transform cells. Therefore, there is cooperation between oncogenic partners, such as RAS, and inactivation of tumor suppressors such as p53 in c-MYC dependant tumor development [@bib239], [@bib240], [@bib241]. Hence, along with passive adaptation of tumor cells, oncogenic mutations and transcriptional controls, such as the reciprocal association of c-MYC with several miRNAs, enhance the ability of cancer cells to consume non-glucose substrates and fuel mitochondria. This may explain the inefficiency of drugs which only target glycolysis and add another layer of complexity to therapeutic strategies.

5.3. PI3K/AKT pathway {#sec5.3}
---------------------

The PI3K intracellular signaling pathway plays a critical role in cell apoptosis, proliferation, and protein synthesis. Its role in regulation of glucose uptake and metabolism is equally definitive. PI3K dysregulation was reported in several human cancers and several drugs targeting this pathway are currently in clinical trials [@bib253]. Activation of PI3K leads to an upregulation of downstream effectors such as AKT and mTOR.

The evolutionarily conserved serine/threonine kinase, AKT, was reported to be one of the most prevalent and constitutively activated onco-proteins in malignant cells [@bib254], [@bib255]. AKT is an important activity-dependent stimulus for cancer cell metabolism, influencing glycolysis by both direct and indirect mechanisms. AKT plays a central role in the regulation of cellular energy metabolism and glucose homeostasis. It stimulates ATP generation by accelerating both glycolytic and oxidative metabolism with a concomitant increase in oxygen consumption to preserve energy. AKT activation results in ROS generation and, therefore, contributes to tumourigenesis by inducing mutations and facilitating tumor-promoting signaling pathways and inducing mutations [@bib256]. Elevated, AKT-mediated, glycolysis plays a major role in proliferation and survival of transformed cells. AKT increases glucose uptake, directly, by increasing the expression and plasma membrane translocation of glucose transporters (GLUT1, GLUT2, and GLUT4) [@bib257]. It also maintains MMP and promotes the association of HK2 with the mitochondrial outer membrane by mediating HK2 phosphorylation and inhibiting glucose-6 phosphate dissociation from the mitochondrial membrane [@bib258]. This may enhance enzymatic efficiency of the kinase, promote metabolic coupling between glycolysis and OXPHOS, increase ATP synthesis through OXPHOS and decrease susceptibility to apoptosis [@bib256]. Indirectly, AKT activates PFK1 phosphorylation and activation by inducing PFK2 and releases forkhead box O1 (FOXO)-mediated repression of glycolysis. AKT also activates mTORC1 indirectly through phosphorylating and, thus, inactivating TSC2, an mTOR inhibitor [@bib259], [@bib260], [@bib261]. The ability of AKT to increase glucose uptake and glycolysis in tumor cells may also require cooperation from other cancer-associated proteins, such as c-MYC and HIF-1. Although AKT-transformed cells show elevated levels of amino acid and lipid transporters that are linked to cell growth, constitutive activation of AKT renders cells dependent on an extracellular glucose supply for survival [@bib256]. Together these findings demonstrate the coordinated regulation of glycolysis and OXPHOS by oncogenic AKT.

AKT, which is described as "Warburg\'s kinase", provides selective advantages to tumor cells by increasing both glycolysis and OXPHOS [@bib262]. Several miRNAs were reported to modulate *AKT* expression directly by targeting *AKT* mRNA, and protein phosphorylation and/or indirectly regulating its upstream stimuli, such as EGFR and its upstream repressors, such as PTEN ([Figure 2](#fig2){ref-type="fig"}).

While some miRNAs, such as miR-637 in glioma, miR-302a and miR-29b in prostate cancer and miR-143 in bladder cancer, directly bind the *AKT* 3′UTR and inhibit its translation, some other miRNAs, reduce AKT phosphorylation without affecting total AKT levels. For instance, miR-126 reduces AKT phosphorylation by inhibiting by phosphatidylinositol 3-kinase regulatory subunit beta (p85β) [@bib263], [@bib264], [@bib265], [@bib266], [@bib267] ([Table 5](#tbl5){ref-type="table"}).

Other proteins and regulatory factors also contribute to regulating AKT activation in different cell types and conditions. For instance, the over-expression of Rictor, a target of miR-34a and mTORC2 component, causes activation of AKT in glioma stem cells [@bib268]. Rictor activation results in mTORC2 activation and consequently, AKT is further activated by mTORC2 mediated phosphorylation [@bib269]. In breast cancer cells miR-205, which is often downregulated in cancer, targets *HER3* receptor transcripts and supresses the activation of AKT [@bib270]. Protein phosphatase 2 scaffold subunit Abeta (PPP2R1B) is another intermediate in AKT signal transduction, directly interacting with AKT, and is a target of miR-200c in esophageal cancer cells [@bib271]. Al-Khalaf and Aboussekhra [@bib272] showed that miR-141 and miR-146b-5p target an RNA binding protein, AUF1, which has an important role in PI3K/AKT/mTOR pathway regulation. AUF1 binds to and stabilizes *PDK1* mRNA and promotes AKT phosphorylation and activation. AUF1 was also reported to negatively regulate PTEN phosphatase and activate PI3K [@bib273], [@bib274]. Additionally, some *AKT*-targeting miRNAs were shown to regulate drug sensitivity in cancer cells, such as miR-29b and miR-200c that influence chemotherapy responses in prostate and esophageal cancers, respectively [@bib265], [@bib271].

However, the miRNAs that regulate AKT signaling do not act to fully repress AKT and its mediators. Rather, they fine tune expression in a context-specific manner. Therefore, it is likely that *AKT* is not exclusively regulated by specific miRNAs and further, it is not surprising that some miRNAs, such as miR-153 which targets both *PTEN* and *AKT* [@bib275], [@bib276], play complex pleiotropic roles in regulating PI3K/AKT signaling.

Although a number of studies have reported *EGFR* gene amplification in some cancers, post-transcriptional modulation remains a significant cause of EGFR overexpression in cancer cells ([Table 5](#tbl5){ref-type="table"}). For instance, miR-7 was found to regulate expression of multiple effectors of the EGFR signaling pathway, as well as directly targeting *EGFR* mRNA. Zhou and Hu et al. [@bib277] showed that miR-7 overexpression in epithelial ovarian carcinoma (EOC) cells results in reduced expression of *EGFR* without any changes in EGFR phosphorylation. A feedback loop between miR-7 and EGFR was reported [@bib277], [@bib278], as increased EGFR activity results in extracellular-signal-regulated kinase (ERK)-mediated degradation of YAN, which is a miR-7 repressor. Further, miR-7 binds to the *YAN* 3′UTR and represses its expression [@bib279].

PTEN has a central role in cell cycle progression. Although mutational loss of PTEN was reported in some cancers, epigenetic factors, including miRNAs, also regulate *PTEN* expression [@bib280] ([Table 5](#tbl5){ref-type="table"}). Due to the unusually long 3′UTR of *PTEN*, it contains binding sites for many miRNAs, which can reduce its mRNA levels (including miR-32, miR-29, miR-26a/b, miR-217, miR-486, miR-193a, miR-519d) [@bib281], [@bib282], [@bib283], [@bib284], [@bib285], [@bib286], [@bib287], [@bib288], [@bib289] or PTEN translation without affecting its mRNA levels (miR-93, miR-214, miR-221, miR-494, miR-21) [@bib290], [@bib291], [@bib292], [@bib293], [@bib294], [@bib295], [@bib296].

Furthermore, miR-185 in HCC and miR-26a in low-grade glioma alter *PTEN* promoter methylation and play a subordinate role in *PTEN* gene regulation by targeting DNA (cytosine-5)-methyltransferase 1 (*DNMT1*) and enhancer of zeste homolog 2 histone methyltransferase (*EZH2*) [@bib282], [@bib297]. Therefore, along with direct regulation of *PTEN* by the aforementioned miRNAs, several miRNAs regulate *PTEN* through indirect mechanisms. Examples include *PTEN* repression via miR-101 and miR-1 both targeting the *PTEN* activator, membrane-associated guanylate kinase inverted 2 (MAGI-2); as well as *PTEN* induction following the miR-185 targeting of *PTEN* silencer, DNMT1 [@bib297], [@bib298], [@bib299].

High glucose was shown to affect some *PTEN* targeting miRNAs, such as stimulating miR-21 levels in renal cancer or lowering miR-32 levels in HCC, depending on the physiological status of the cells, which results in AKT activation or suppression, respectively [@bib300], [@bib301].

PTEN dephosphorylates PIP3, generated by PI3K, to inhibit AKT activation. Suppression of PTEN, through miRNA-mediated mechanisms, enhances AKT phosphorylation and signaling and supports cell proliferation and survival [@bib302]. PTEN inhibition also results in cystic vestibular schwannoma development and cancer cell invasion via induced metalloproteinase-2 (MMP-2) [@bib303]. Transforming growth factor beta 1 (TGF-β) mediated AKT activation is another consequence of reduced PTEN activity [@bib289], [@bib304]. Decreased *PTEN* expression was also shown to impair p53-dependant responses in cancer cells [@bib286]. Moreover, some miRNAs were shown to induce drug- and radio-resistance by inhibiting *PTEN*. For instance, miR-21 induces daunorubicin resistance in leukemia, miR-214 induces cisplatin resistance in ovarian cancer cells and miR-221 induces TRAIL- and radio-resistance in glioma cells by inhibiting *PTEN* [@bib288], [@bib293], [@bib305]. Breast cancer metastases in the brain also display increased aggression due to suppression of PTEN by astrocyte exosomal miRNAs [@bib306].

5.4. Mechanistic target of rapamycin kinase (mTOR) {#sec5.4}
--------------------------------------------------

Mechanistic target of rapamycin (mTOR), also known as mammalian target of rapamycin, consists of two divergent complexes: complex 1 (mTORC1) and (mTORC2). mTORC1 acts as a metabolic hub, integrating extracellular stimuli with nutrient availability and cellular energy to coordinate responses. mTORC1 is mainly involved in cellular proliferation, translation and metabolic programming while mTORC2 regulates cell survival, cytoskeletal organization, and degradation of newly synthesized polypeptides [@bib307], [@bib308].

mTOR is stimulated by loss of function of some inhibitors including LKB1, PML, PTEN, and TSC1/2 or activation of some oncogenes such as *AKT* and *RAS* [@bib115], [@bib116], [@bib262], [@bib309]. Activated mTOR, in turn, dramatically enhances the translational machinery and ribosome biogenesis, increases cell growth in response to mitogens, growth factors and hormones, and upregulates some transcription factors [@bib310]. It also activates several glycolytic enzymes such as GLUT1, LDHA, PKM2, and HK2 [@bib311], [@bib312], [@bib313]. The connection between hypoxia and mTOR is of particular interest. Although it has been shown that mTOR is able to induce *HIF-1* translation, mTOR activity is reduced in hypoxia, likely through negative feedback [@bib314], [@bib315]. Hypoxia-mediated inhibition of mTOR could be through activation of tuberous sclerosis protein (TSC1/2) via AMPK, REDD1 or BNIP3 activation [@bib117], [@bib309], [@bib316], [@bib317]. However, there is also evidence that hypoxia-mediated inhibition of mTOR is more prevalent in normal cells compared with cancer cells [@bib318]. Therefore, it may be concluded that mutations in the mTOR signaling pathway account for the reduced hypoxia-mediated mTOR inhibition. It was discovered that mTOR, along with p53, spares the available serine for glutathione synthesis by stimulation of PKM2 protein synthesis, which links glycolysis to anabolic pathways [@bib319]. Moreover, mTOR suppresses autophagy and mitophagy and, therefore, produces ROS. AMP-activated protein kinase (AMPK), an mTOR inhibitor, plays a vital role in metabolic flux and regulates *GLUT4* expression, mitochondrial biogenesis and fatty acid oxidation. Complex interaction between mTOR, AKT, and AMPK to regulate *GLUT4* translation has also been shown [@bib320]. Activated AKT phosphorylates and inhibits AS160 Rab GTPase activating protein in the cytoplasm leading to increased translocation of the insulin-responsive glucose transporter, GLUT4 to the membrane [@bib321]. Also, ADP and ATP play a critical role in the stability of AKT phosphorylation at residues T308 and S473 and, therefore, act as on/off switches as ATP binds to these phosphorylated sites and protects them against phosphatases. Consequently, AMPK regulates AKT phosphorylation by responding to the equilibrium of the adenylate pool [@bib320], [@bib322]. On the other hand, Kumar et al. [@bib323], reported that FRic^−/−^ murine fat cells, with ablated Rictor, showed impaired insulin-stimulated GLUT4 translocation to the plasma membrane and decreased glucose transport.

Given the integral role that mTOR plays in oxygen and nutrient sensing, it is notable that several miRNAs may directly or indirectly influence mTOR activity. Increased expression of *MTOR* coexists with downregulation of several miRNAs in various types of cancer ([Table 5](#tbl5){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}). Examples include miR-99a/b, miR-100, and miR-199b in cancers, including endometrial cancer, esophageal squamous cell carcinoma, and bladder cancer [@bib324], [@bib325], [@bib326], [@bib327]. miR-99 and miR-100 were also reported to be endogenous inhibitors of mTOR protein abundance [@bib328]. miR-7 was found to target *MTOR* directly and form a negative feedback loop by also directly repressing EGFR and thus results in pleiotropic inhibition of protein translation [@bib329], [@bib330]. Chen et al. and Lin and Shao et al. [@bib331], [@bib332] reported a significant inhibition of mTOR expression, at both RNA and protein levels, by miR-101. Also, miR-373 and miR-520c were reported to reduce *MTOR* mRNA and protein levels and increase MMP9, which consequently results in the increased migration and invasion capability of cancer cells [@bib333]. A negative regulator of mTOR is TSC1/2 complex. miR-451 was found to target TSC1 and stimulate the stemness phenotype of myeloma cells through activation of the PI3K/AKT/mTOR pathway [@bib334], [@bib335]. These findings further highlight the role of mTOR, situated at the crossroads of cancer-related signaling pathways. They show the interplay between components of signaling cascades and miRNAs, with practical implications for cancer therapy.

5.5. Tumor protein p53 (TP53) {#sec5.5}
-----------------------------

p53 is a transcription factor and tumor suppressor that plays critical roles in controlling cell cycle progression through DNA damage response and apoptosis, which has been shown to regulate both glycolysis and OXPHOS [@bib190]. In general, p53 inhibits glycolysis transcriptionally by supressing *GLUT1*, *GLUT3*, and *PGM* expression. Therefore, loss of p53 function in many cancers contributes to either glycolysis or the pentose phosphate pathway (PPP) [@bib155], [@bib336]. Mutated p53 was shown to reduce oxygen consumption and mitochondrial respiration. First, diminished p53 activity reduces OXPHOS by eliminating its suppression of SCO2, a protein essential for COX assembly and mitochondrial respiration [@bib337]. Moreover, p53 may affect mtDNA by regulating the expression of ribonucleotide reductase subunit p53R2 and, ultimately, regulating mitochondrial oxidative respiration [@bib338]. P53R2 plays important roles in both the biogenesis of mitochondria and mtDNA maintenance [@bib339]. Although p53 induces oxidative stress by its pro-apoptotic function, it can also adversely impact redox maintenance [@bib340]. Anti-oxidant roles of p53 include upregulation of GLS2 and subsequent increase in glutathione as well as enhanced stability of NRF2, an important antioxidant transcription factor, under oxidative stress [@bib341], [@bib342]. Other p53 functions that regulate metabolism include induced *PTEN* expression, which inhibits the PI3K pathway and glycolysis, cooperation with the OCT1 transcription factor to modulate the balance between glycolysis and OXPHOS and reduced fatty acid oxidation in response to metabolic flux [@bib343], [@bib344], [@bib345].

The identification of several miRNAs that target p53 implies complex regulation and may explain the development of malignancies in cells with wild-type p53, where miRNA-mediated repression of *TP53* and its transactivational genes, such as *CDKN1A*, *BBC3*, *DNM1L*, and *BAX*, is sufficient to cause tumourigenesis [@bib346], [@bib347]. p53 both regulates, and is regulated by, miRNAs. Many of these miRNAs were shown to directly target *TP53* in different systems (summarized in [Table 5](#tbl5){ref-type="table"}). It is becoming clear that most of these miRNAs represent conservative regulation of p53 activity, targeting multiple components of the p53 pathway. Also, the functional overlap between these miRNAs indicates the potential for cumulative miRNA dysregulation influencing the p53 network during tumourigenesis. p53 suppresses glucose transporters and glycolytic enzymes by enhancing TIGAR [@bib348]. TIGAR is best characterized by its negative regulation of fructose-2, 6-bisphosphatase. Eventually, TIGAR directs glucose to PPP and enhances NADPH production [@bib349]. miR-144 targets TIGAR and modulates autophagy, apoptosis and metastasis in lung cancer cells [@bib350]. In order to survive, cancer cells can also render p53 inactive by point mutation or through degradation induced by the E3 ubiquitin ligase, (MDM2) [@bib351], [@bib352]. Aside from gene mutations, promoter (de)methylation and proteolytic degradation, *MDM2* is regulated by miRNAs. miRNAs such as miR-605 and miR-660 directly target *MDM* and modulate MDM:p53 interaction, aiding rapid stabilization and accumulation of p53. On the other hand, p53 trans-activates the expression of the miR-605 host gene *PRKG1* through binding to its promoter region, which results in a positive feedback loop and increased p53 activity [@bib353], [@bib354]. Other miRNAs that suppress *MDM2* include miR-509-5p in HCC and cervical cancer, miR-29b in non-small cell lung cancer (NSCLC), miR-143/145 in head and neck squamous cell carcinoma (HNSCC), miR-192, miR-215, miR-194, and miR-339-5p in renal cell adenocarcinoma, breast cancer, and colorectal cancer [@bib355], [@bib356], [@bib357], [@bib358] ([Figure 2](#fig2){ref-type="fig"}).

In addition to the aforementioned functions of p53 in regulating cell metabolism, miRNA biosynthesis also involves p53-signaling components. p53 interacts with the Drosha complex and accelerates the processing of targeted primary miRNA sequences to precursor miRNA fragments [@bib359]. Specific miRNAs are also transcriptionally regulated by p53 [@bib355], [@bib360], [@bib361] ([Table 4](#tbl4){ref-type="table"}). Most of these p53-responsive miRNAs are involved in both positive and negative feedback loops. For instance, members of the miR-34 family are induced through p53 binding to their promoter in response to stress and, in turn, *TP5*3 mRNA has been validated as a direct target of miR-34 [@bib362], [@bib363]. miR-605 and miR-509-5p/MDM2/p53 are examples of positive feedback loops where p53 induces miRNA synthesis and miR-509-5p and miR-605 target *MDM2* to increase p53 protein levels [@bib353], [@bib355]. miR-17-5p/TP53INP1/p53 is another regulatory feedback loop. miR-17-5p targets TP53INP1 mRNA transcript which encodes a p53-induced nuclear protein and also is a direct target of p53; so, miR-17-5p functions as a mediator in a regulatory loop in colon and cervical cancer [@bib361]. Other miRNAs that target tumor protein P53 inducible nuclear protein 1 (*TP53INP1*) include miR-130b in hepatocarcinoma, miR-155 in pancreatic cells, and miR-125b in endometrial carcinoma [@bib364], [@bib365], [@bib366]. Therefore, both regulation of the p53 network by miRNAs, and p53 induction of miRNA levels, are tightly coordinated to enable response to stimuli.Table 4Summary of miRNAs regulated by the transcription factor p53.Table 4miRNARegulationDisease/cellsReferencesLet-7a/bDownregulationColorectal Cancer[@bib367]miR-17DownregulationColorectal Cancer[@bib133]miR-20aDownregulationColorectal Cancer[@bib133]miR-29UpregulationColorectal Cancer[@bib368]miR-200cUpregulationMammary Gland, Colorectal Cancer[@bib369], [@bib370]miR-183UpregulationMammary Gland[@bib369]miR-34a/b/cUpregulationColorectal Cancer, Non-Small Cell Lung Cancers, Ovary Clear Cell Carcinoma, Osteosarcoma, Pancreatic Cancer, Prostate Cancer, Ovarian Carcinoma[@bib362], [@bib371], [@bib372], [@bib373], [@bib374], [@bib375]miR-605UpregulationBreast Cancer, Lung Carcinoma[@bib353]miR-145UpregulationBreas Cancer, Colorectal Cancer[@bib241]miR-192UpregulationColorectal Cancer, Multiple Myeloma, Ovary Clear Cell Carcinoma, Osteosarcoma[@bib358], [@bib370], [@bib372], [@bib376]miR-194UpregulationMultiple Myeloma, Colorectal Cancer[@bib358], [@bib376]miR-215UpregulationColorectal Cancer, Multiple Myeloma, Ovary Clear Cell Carcinoma, Osteosarcoma[@bib358], [@bib370], [@bib372], [@bib376]miR-141UpregulationColorectal Cancer[@bib370]miR-519dUpregulationHepatocellular Carcinoma[@bib286]miR-107UpregulationColorectal Cancer[@bib151], [@bib377]miR-509UpregulationCervical Cancer, Hepatocellular Carcinoma[@bib355]

These findings show that the p53 network is more complex than previously envisioned and suggest that additional regulatory layers, incorporating miRNAs, provide derepression of *TP53* enabling it to accumulate rapidly in response to cell stress. The aforementioned functions establish a new driver of the Warburg effect and demonstrate that p53 may act as a "brake" on glycolysis and neoplastic cell proliferation.

5.6. Sirtuins {#sec5.6}
-------------

Sirtuins are a conserved family of NAD^+^-dependent deacetylases. Advances in sirtuin biology have identified multiple targets for the seven mammalian sirtuins (SIRT1-7) and, recently, their participation in tumourigenesis and regulation of cancer cell metabolism [@bib378].

SIRT1 is a nuclear protein that shuttles between the nucleus and cytoplasm, especially when insulin signaling is inhibited [@bib379]. SIRT1 modulates several cellular pathways by deacetylating a subset of nuclear and cytosolic targets. AMPK and SIRT1 cooperate in the induction of gluconeogenesis, glycolysis and lipid catabolism, mitochondrial biogenesis and respiration by phosphorylation and then deacetylation of PPARgamma coactivator 1alpha (PGC1α) and FOXO transcription factors [@bib380], [@bib381], [@bib382], [@bib383]. A homeostatic and negative feedback loop has been reported among SIRT1, p53, FOXO3A, and FOXO1. During energy stress FOXO3A binds to p53 promoter, repressing SIRT1 expression, and in turn SIRT1 inhibits p53 activity by excessive deacetylation and also through FOXO3A activation [@bib384], [@bib385], [@bib386]. In addition, SIRT1 is involved in the oxidative response, working together with HIF-1, p53, and Myc [@bib387].

SIRT6 is another member of the sirtuin nuclear histone deacetylase (HDAC) family, which exerts both nuclear ADP-ribosyltransferase activity and deacetyltransferase activity with roles in epigenetic regulation of genomic stability, cellular metabolism, stress response, aging, and cancer [@bib388], [@bib389], [@bib390], [@bib391]. Yin and Gao et al. [@bib392] showed that neuronal SIRT6 overexpression significantly suppresses insulin-like factor 2 (IGF2) activity and other proteins such as AKT and mTOR at the chromatin level. SIRT6 activation results in inhibition of HIF-1, glycolysis, and respiration, as well as induction of homologous and non-homologous DNA repair. The latter function of SIRT6 occurs through ADP-ribosylation of poly(ADP-Ribose) polymerase 1 (PARP-1) [@bib393], [@bib394]. SIRT6 regulates *HIF-1* and *c-Myc* expression, at the transcriptional level, through chromatin deacetylation and also regulates HIF-1 stability through an unknown mechanism [@bib395]. Mostoslavsky et al. [@bib396] reported a novel role for SIRT6 in glucose homeostasis in mice. Accordingly, subsequent studies confirmed its vital role in direct and indirect regulation of glucose uptake and metabolism. Nevertheless, SIRT6 was found to transcriptionally regulate some c-Myc targets involved in ribosomal biogenesis and glutamine utilization, rather than those involved in regulating cancer cell glycolysis [@bib397]. In contrast to SIRT6 that acts independently, SIRT1 cooperates with c-Myc to suppress p53 activity and increase c-Myc-induced *LDHA* expression [@bib395]. SIRT7 is a nucleolar sirtuin member that activates transcription by binding to RNA polymerase [@bib398], [@bib399]. Vakhrusheva et al. [@bib400] reported a p53 hyperacetylation state in SIR7 knockout mice, which results in increased apoptosis and decreased resistance to oxidative stress.

The miRNA-mediated regulation of nuclear sirtuins, with an emphasis on SIRT1 and SIRT6, has highlighted their roles in glycolysis. SIRT1 has been the most extensively studied member in this context. miR-34a was the first discovered *SIRT1* targeting miRNA. miR-34 is a p53-related miRNA that most importantly regulates cell cycle. miR-34 downregulates *SIRT1* expression by directly binding to its 3′UTR and indirectly through targeting nicotinamide phosphoribosyltransferase (NAMPT), the rate limiting enzyme in NAD^+^ biosynthesis [@bib401], [@bib402], [@bib403]. Xu et al. [@bib404] reported *SIRT1* targeting by miR-22, which modulates the retinoblastoma signaling pathway. miR-204 targets *SIRT1* in osteocarcinoma cells and inhibits epithelial--mesenchymal transition (EMT) of the cancer cells [@bib405]. Similarly, miR-200c has been reported to form a negative feedback loop with SIRT1, attenuating epithelial to mesenchymal transition (EMT) in breast cancer cells [@bib406]. Likewise, miR-181a and miR-9 regulate *SIRT1* and impact insulin signaling, glucose homeostasis and cell apoptosis [@bib407], [@bib408], [@bib409]. miR-143, miR-93 and miR-217 lead to decreased glucose uptake, downregulated microsomal glutathione S-transferase 1 and inhibited angiogenesis, respectively, by targeting *SIRT1* [@bib410], [@bib411], [@bib412]. Several other miRNAs that modulate *SIRT1* expression and activation include miR-9, miR-34c, miR-132, miR-135, miR-146, miR-181b, miR-195, miR-199, and miR-499 [@bib413], [@bib414], [@bib415], [@bib416], [@bib417] ([Figure 2](#fig2){ref-type="fig"}).

Post-transcriptional regulation of *SIRT6* by miR-33a/b plays a vital role in regulation of cholesterol and lipid metabolism via acetylation of its targets [@bib392], [@bib418], [@bib419], [@bib420]. Sharma et al. [@bib421] reported a negative feedback loop between SIRT6 and miR-766 in dermal fibroblasts. *SIRT7* expression is elevated in highly metabolic and proliferative cells and was reported to be a target of miR-125a/b inducing G1 cell cycle arrest [@bib422].

SIRT2 is predominantly cytosolic but it also shuttles to the nucleus and is mainly enriched in the brain [@bib423]. SIRT2 was reported to deacetylate histone H3, p300, FOXO1, FOXO3A, adenomatous polyposis coli (APC), cell division cycle 20 (CDC20), p65, PGM, phosphoenolpyruvate carboxykinase 2 (PEPCK), and receptor-interacting protein 1 (RIP1) and, therefore, regulates cell cycle, genome integrity, energy homeostasis, gluconeogenesis, glycolysis, oxidative stress modulation, cell growth, and death [@bib424], [@bib425], [@bib426], [@bib427], [@bib428], [@bib429], [@bib430]. miR-339 was shown to target SIRT2, increasing NF-KB and FOXO1 acetylation in neuroblastoma cells [@bib431]. Moreover, *in silico* analysis revealed a longevity associated SNP of *SIRT2* within the binding site of three miRNAs (called miRSNPs). Therefore, miR-3170, miR-92a-1-5p and, more importantly, miR-615-5p were predicted to target *SIRT2* resulting in reduction in *SIRT2* expression [@bib432]. Li and Dai et al. [@bib284] showed that *SIRT2* is downregulated in glioma. SIRT2 acts as a tumor suppressor and inhibits glioma growth by targeting miR-21 expression through deacetylating p65 and blocking p65 binding to the miR-21 promoter. Regulation of miR-21 activity is particularly important as this miRNA displays significant oncogenic activity [@bib433].

Three mitochondrial sirtuins are SIRT3, SIRT4, and SIRT5. SIRT3 is the major mitochondrial sirtuin, which promotes ATP production by regulating TCA cycle enzymes such as acetyl COA synthetase, IDH2, glutamate dehydrogenase 1 (GDH) and SDH during energy stress. GDH upregulation leads to an induction in glutamine metabolism which consequently produces more ATP and releases insulin [@bib434], [@bib435], [@bib436], [@bib437]. It also upregulates Mn superoxide dismutase (MnSOD), downregulates ROS, HIF-1, and p53 and activates FOXO3A to modulate redox homeostasis and maintain mitochondrial membrane potential [@bib438], [@bib439], [@bib440], [@bib441], [@bib442]. SIRT3-mediated regulation of OXPHOS components has been shown. The targets include components of complex I, II, III and V such as NDUFA11/S8, SDHA/B and ATP5A1/B1/F1 [@bib438], [@bib443], [@bib444]. Altogether, SIRT3 is capable of reversing the Warburg effect toward mitochondrial predominance and ATP synthesis. SIRT4 is another mitochondrial sirtuin which seems to function as a tumor suppressor by downregulating GDH through ADP-ribosylation activity and consequently suppressing glutamine utilization and the flow of amino acids into the TCA cycle [@bib434]. Nasrin et al. [@bib445] showed that reduced SIRT4 results in increased fatty acid oxidation and mitochondrial metabolism. They also demonstrated an increase in *SIRT1* expression levels. miR-193 mediated suppression of SIRT3 leads to impaired energy metabolism and ATP synthesis in myocardium [@bib446]. miR-23a was also shown to target *PGC1* and thereby indirectly modulate *SIRT3* expression [@bib447]. Moreover, upregulation of miR-28-5p, resulting from oxidative stress, directly targets *SIRT3* [@bib448]. Liang et al. [@bib449] reported SNPs in the miR-105 and miR-532 binding sites in the *SIRT3* 3′UTR that are associated with ovarian cancer treatment responses. In addition, Slaby et al. [@bib450] reported three miRNAs that are regulated by natural agents called isothiocyanates in colorectal cancer (CRC) cells. *In silico* analysis also revealed CRC-related SNPs within the 3′UTR of genes, including *SIRT5*, may influence binding of these isothiocyanate-regulated miRNAs.

Collectively, SIRTs play important roles in a wide range of metabolic pathways and interact with many transcriptional regulators. miRNAs targeting SIRTs (summarized in [Table 5](#tbl5){ref-type="table"}) may modulate SIRT-related signaling transduction and downstream effectors, providing insight into novel therapeutic strategies.Table 5Summary of miRNAs targeting metabolism-related oncogenes and tumor suppressors S indicates references in [Supplementary file](#appsec2){ref-type="sec"}.Table 5miRNAsGeneDiseaseReferencesLet-7***KRAS, MYC***Breast Cancer, Colorectal Cancer, Lung Cancer, Glioma, Malignant Mesothelioma, Oropharyngeal Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Prostate Cancer, Burkitt Lymphoma, Malignant Bronchial Epithelial Cell, Pulmonary HypertensionS \[1--8\], [@bib199], [@bib205], [@bib224], [@bib234], [@bib236]miR-1***KRAS, EGFR, PTEN***Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma, Cardiovascular DiseaseS \[9--11\], [@bib298]miR-100***mTOR***Esophageal Squamous Cell Carcinoma, Bladder Cancer, Endometrioid Endometrial Carcinoma, Breast CancerS \[12\], [@bib325], [@bib326], [@bib327]miR-101***KRAS, MYC, AKT, mTOR, TIGAR***Hepatocellular Carcinoma, Osteosarcoma, Clear Cell Renal Cell Carcinoma, Prostate CancerS \[13--15\], [@bib331], [@bib332]miR-105***SIRT3***Ovarian Cancer[@bib449]miR-106a/b***SIRT1, PTEN***Pituitary Tumor, Breast CancerS \[16--18\]miR-107***EGFR***Non-Small Cell Lung CancerS \[19\]miR-10b***PTEN***Breast CancerS \[20\]miR-122/a***MYC, EGFR***Hepatocellular Carcinoma, Inflammatory Bowel DiseaseS \[21\], [@bib231]miR-124a***SIRT1***Neuropathic PainS \[22\]miR-125a/b***SIRT1, SIRT7, TP53***Hepatocellular Carcinoma, Age-Related Cataract, Multiple Myeloma, Non-Small Cell Lung Cancer, Colorectal Cancer, Neuroblastoma, CataractS \[23--28\], [@bib422]miR-126***KRAS, AKT***Pancreatic Cancer, Squamous Tongue Cell Carcinoma, Glioma, Colorectal CancerS \[29,30\], [@bib204], [@bib263]miR-1285***TP53***Neuroblastoma, HepatoblastomaS \[31\]miR-1294***MYC***Esophageal Squamous Cell CarcinomaS \[32\]miR-1297***PTEN***Breast CancerS \[33\]miR-130a/b***MYC, PTEN***Osteocarcinoma, Bladder Carcinoma, Non-small Cell Lung CancerS \[34--36\], [@bib223]miR-132***SIRT1***Glioma, Type2 Diabetes Mellitus, Gastric Cancer, ColitisS \[37--40\]miR-133a/b***EGFR, SIRT1***Pancreatic Cancer, Ovarian Cancer, Hepatocellular CarcinomaS \[41,42\]miR-134***KRAS, EGFR***Rena Cell Carcinoma, Glioblastoma, Non-Small Cell Lung Cancer, Colorectal CancerS \[43--45\], [@bib207]miR-135a/a-1***MYC, EGFR***Renal Cell Carcinoma, Prostate CancerS \[46,47\]miR-137***EGFR***Glioblastoma Multiforme, Thyroid CancerS \[48,49\]miR-138***SIRT1***Diabetic Vascular Smooth Muscle Cells, Intervertebral Disc Degeneration, Pancreatic Cancer, OsteocarcinomaS \[50--53\]miR-141***PTEN, AKT, TP53, SIRT1***Esophageal Cancer, Osteosarcoma, Multiple Myeloma, Pluripotent Stem Cells, Glioma, HB infectionS \[25,54--57\], [@bib272]miR-142***PTEN***Cutaneous Squamous Cell CarcinomaS \[58\]miR-143***KRAS, EGFR, AKT, MDM2, SIRT1***Colorectal Cancer, Non-Small Cell Lung Cancer, Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Pancreatic CancerS \[59--63\], [@bib266], [@bib357], [@bib410]miR-144***PTEN, mTOR, TIGAR***Pancreatic Neuroendocrine Tumor, Preeclampsia, Salivary Adenoid Carcinoma, Renal Cell Carcinoma, Inflammation of Microglia, Lung CancerS \[64--67\], [@bib350]miR-145***MYC, MDM2, SIRT1***Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Ovarian Cancer, Oral Squamous Cell Carcinomas, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Pancreatic CancerS \[68--70\], [@bib266], [@bib357], [@bib410]miR-146b***AKT***Osteosarcoma[@bib272]miR-148a/b***PTEN, AKT, MYC***Osteosarcoma, Renal Cell Carcinoma, Hepatocellular CarcinomaS \[71,72\], [@bib2], [@bib229]miR-149***AKT***Hepatocellular Carcinoma, Neuroblastoma, Glioblastoma MultiformeS \[73--75\]miR-150***TP53***Lung CancerS \[76\]miR-152***PTEN, SIRT7***Hepatic Insulin Resistance, Human Dental Pulp Stem CellsS \[77,78\]miR-153***PTEN, AKT***Prostate Cancer, Lung Cancer[@bib275], [@bib276]miR-155***KRAS, MYC, PTEN, AKT, SIRT5, SIRT1***Gastric Carcinoma, hepatocellular Carcinoma, Waldenström Macroglobulinemia, Leukemia, Colorectal Cancer, Neuropathic PainS \[22,79--81\], [@bib220], [@bib301], [@bib450]miR-15a/b, miR-16***TP53, mTOR, AKT, SIRT4***Multiple Myeloma, Glioma, Ischemia, Dermal FibroblastsS \[25,82--85\]miR-17***MYC, TP53***Neuroblastoma, Cervical CancerS \[86\], [@bib361]miR-18/a***KRAS***Human Squamous Carcinoma, Colorectal Cancer, Liver Cancer, Ovarian CancerS \[87,88\]miR-181a/b/d***PTEN, KRAS, EGFR, AKT, SIRT1***Colorectal Cancer, Osteosarcoma, Oral Squamous Cell Carcinoma, Glioma, Cutaneous Squamous Cell Carcinoma, Acute Myeloid Leukemia, Glioblastoma Multiforme, Hepatic Stellate Cells, Non-Alcoholic Fatty Liver DiseasesS \[89--97\]miR-1827***MDM2***Colorectal CancerS \[98\]miR-183***mTOR***Neuropathic PainS \[99\]miR-184***MYC***Non-Small Cell Lung Cancer, Nasopharyngeal CarcinomaS \[100,101\]miR-185***MYC, PTEN, AKT***Colorectal Cancer, Breast Cancer, Hepatocellular Carcinoma, Idiopathic Pulmonary Fibrosis, Non-Small Cell Lung CancerS \[102--104\], [@bib228], [@bib297]miR-192***MDM2***Colorectal Cancer, Multiple Myeloma[@bib358], [@bib376]miR-193a/b***PTEN, KRAS, TSC1/2***Renal Cell Carcinoma, Colon Cancer, Breast Cancer, Pancreatic Ductal Adenocarcinoma, Cutaneous Squamous Cell Carcinoma, Amyotrophic Lateral SclerosisS \[105--108\], [@bib202], [@bib208]miR-194***AKT, MDM2***Gall Bladder Cancer, Multiple MyelomaS \[109\], [@bib358], [@bib376]miR-195***SIRT3***Myocardium[@bib446]miR-197***TP53***Non-Small Cell Lung CancerS \[110\]miR-199a/b***SIRT1, mTOR***Pluripotent Stem Cells, Hyperglycemia-Induced Pancreaticβ-Cell Loss, Endometrioid Endometrial CarcinomaS \[111,112\], [@bib325]miR-19a/b***PTEN, TP53***Bladder Cancer, Osteosarcoma, Myeloma, Liver Cancer, Breast CancerS \[113--116\]miR-200a/c***EGFR, TP53, KRAS, PTEN, SIRT1, MYC, AKT***Bladder Cancer, Breast Cancer, Multiple Myeloma, Nasopharyngeal Carcinoma, Colorectal Cancer, Hepatic Stellate Cell, Pluripotent Stem Cell, Lung Adenocarcinoma, Renal Cell Carcinoma, Ovarian Cancer, Esophageal CancersS \[25,117--126\], [@bib271], [@bib334]miR-203***MYC***Cutaneous Squamous Cell CarcinomaS \[127\]miR-204***SIRT1***Osteosarcoma, Spermatogonial Stem Cell, Hepatocellular CarcinomaS \[128,129\], [@bib405]miR-205***PTEN***Ovarian CancerS \[130\]miR-206***KRAS, EGFR***Gastric Cancer, Pancreatic Ductal Adenocarcinoma, Oral Squamous Cell Carcinoma, Head and Neck Squamous Cell CarcinomaS \[10,131--133\]miR-20a/b***PTEN, AKT, SIRT7***Coronary Artery Disease, Diabetic Retinopathy, Diabetic NephropathyS \[134--136\]miR-21***KRAS, MYC, PTEN***Lung Cancer, Breast Cancer, Diabetic Kidney Disease, Colorectal Cancer, Hepatocellular Carcinoma, Leukemia, Vestibular Schwannomas, Glioblastoma, Bladder Cancer, Radio-resistance Lung CancerS \[5,137--142\], [@bib296], [@bib305]miR-210***MYC***Colorectal Cancer, Glioblastoma, Cervical Cancer, Breast CancerS \[143\]miR-212***SIRT1***Prostate CancerS \[144\]miR-214***KRAS, PTEN, TP53***Non-small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Ovarian Cancer Stem CellsS \[145--148\], [@bib291]miR-215***MDM2***Colorectal Cancer, Multiple Myeloma[@bib358], [@bib376]miR-216a/b***PTEN, KRAS***Acute Pancreatitis, Kidney Disorders, Ovarian Cancer, Nasopharyngeal CarcinomaS \[149--151\], [@bib289]miR-217***KRAS, PTEN, SIRT1***Pancreatic Ductal Adenocarcinoma, Lung Cancer, Kidney Disorders, Podocyte Injury, AgingS \[152--154\], [@bib289], [@bib411]miR-218***EGFR, mTOR***Non-Small Cell Lung Cancer, Prostate CancerS \[155,156\]miR-22***MYC, PTEN, SIRT1***Leukemia, Clear Cell Renal Cell Carcinoma, Glioblastoma, Ischemia-Reperfusion InjuryS \[157--161\], [@bib225]miR-221***PTEN***Radiosensitive Cancer Cells, GlioblastomaS \[162\], [@bib293]miR-222***PTEN, TP53***Radiosensitive Cancer Cells, Oral Squamous Cell CarcinomaS \[162\], [@bib346]miR-224***KRAS, mTOR***Colorectal Cancer, Gastric CancerS \[163,164\]miR-23a/b***EGFR, SIRT5, SIRT1***Coronary Artery Disease, Colorectal Cancer, Diabetic RetinopathyS \[165,166\], [@bib450]miR-24***MYC, TP53***Leukemia, Embryonic Stem Cells, Hepatocellular CarcinomaS \[167,168\], [@bib227]miR-25***PTEN, TP53***Diabetic Nephropathy, Multiple Myeloma, Non-Small Cell Lung Cancer, Colorectal CancerS \[25,169,170\]miR-26a***PTEN***Glioblastoma[@bib282]miR-27a/b***KRAS, TP53, EGFR, SIRT5***Esophageal Squamous Cells Carcinoma, Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung CancerS \[47,171--173\], [@bib450]miR-28***SIRT3***Primary human tenocytes[@bib448]miR-29a/b/c***PTEN, AKT, MDM2***Colorectal Cancer, Gastric Cancer, Prostate Cancer, Breast Cancer, Non-Small Cell Lung CancerS \[174--177\], [@bib265], [@bib288], [@bib356]miR-300***TP53***Lung Cancer, Colorectal CancerS \[178,179\]miR-301a***PTEN***Pancreatic Cancer, Malignant MelanomaS \[180,181\]miR-302a***AKT***Prostate Cancer[@bib264]miR-30b/c/d***KRAS, TP53***Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Multiple Myeloma, Cardiac DiseaseS \[170,182--184\], [@bib347]miR-31***TP53***Breast CancerS \[185\]miR-3151***TP53***Malignant MelanomaS \[186\]miR-32***PTEN***Hepatocellular Carcinoma[@bib287]miR-320a***MYC***Hepatocellular CarcinomaS \[187\]miR-33***TP53***Hematopoietic Stem CellsS \[188\]miR-337***PTEN***Endometrial CarcinomaS \[189\]miR-338***mTOR***Colon CancerS \[190\]miR-339***MDM2, SIRT2***Breast Cancer, NeuroblastomaS \[191\], [@bib431]miR-33a/b/c***SIRT6, MYC***Liver Cancer, Osteosarcoma[@bib219], [@bib418]miR-340***MDM2***Prostate CancerS \[192\]miR-34a***MYC, EGFR, AKT, SIRT6, SIRT1***Hepatocellular Carcinoma, Prostate Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Glioma, Colorectal Cancer, Non-Alcoholic Fatty Liver Diseases, Pancreatic CancerS \[193--197\], [@bib222], [@bib240], [@bib268], [@bib410]miR-363***MYC***Prostate Cancer, Hepatocellular CarcinomaS \[198\], [@bib2]miR-365a***KRAS***Cutaneous Squamous Cell CarcinomaS \[106\]miR-3666***SIRT7***Breast CancerS \[199\]miR-367***MDM2***Hepatocellular CarcinomaS \[200\]miR-370***EGFR, PTEN***Gastric Cancer, Colorectal Cancer, Gastric CancerS \[45,201,202\]miR-373***mTOR, SIRT1***Fibrosarcoma[@bib333]miR-374/a***MDM2, PTEN***Bladder Cancer, Breast CancerS \[203,204\]miR-377***SIRT1***ObesityS \[205\]miR-378***AKT***Breast CancerS \[206\]miR-380***TP53***NeuroblastomaS \[207\]miR-384***KRAS***Colorectal CancerS \[208\]miR-409***AKT***Breast CancerS \[209\]miR-421***SIRT3***Non-Alcoholic Fatty Liver DiseaseS \[210\]miR-429***MYC***Gastric Cancer, Breast CancerS \[119,211\]miR-449a/c***MYC***Glioblastoma, Gastric Carcinoma, Osteosarcoma, Prostate CancerS \[212--214\]miR-451***MYC, AKT***Docetaxel-Resistant Lung Adenocarcinoma, Dilated Cardiomyopathy, Bladder Cancer, Non-Small Cell Lung Cancer, GlioblastomaS \[215--220\]miR-451***TSC1/2***Multiple Myeloma, Hypertrophic CardiomyopathyS \[221\], [@bib335]miR-453***TP53***Lung CancerS \[222\]miR-4534***PTEN***Prostate CancerS \[223\]miR-454***PTEN***Non-Small Cell Lung CancerS \[224\]miR-4689***KRAS, AKT***Colorectal Cancer,[@bib203]miR-486***PTEN, MDM2, SIRT1***Cardiac Myocytes, Lung Cancer, ErythroleukemiaS \[225,226\], [@bib283]miR-491***TP53***Pancreatic CancerS \[227\]miR-492***PTEN***Hepatic CancerS \[228\]miR-494***MYC, PTEN, SIRT1***Epithelial Ovarian Cancer, Cardiac Disease, Myeloid-Derived Suppressor Cells, Cervical Cancer, Gastric Carcinoma, Pancreatic CancerS \[229--233\], [@bib294], [@bib304]miR-495***AKT, mTOR***Prostate CancerS \[234\]miR-496***mTOR***AgingS \[235\]miR-5003***MDM2***Breast CancerS \[236\]miR-502a***EGFR***Colorectal CancerS \[237\]miR-504***TP53***Non-Small Cell Lung Cancer, Colorectal Cancer, Multiple Myeloma, Abdominal Aortic AneurysmS \[170,238\], [@bib360]miR-509***EGFR, MDM2***Tongue Squamous Cell Carcinoma, Cervical Cancer, Hepatocellular Carcinoma, Prostate CancerS \[239,240\], [@bib355]miR-511***AKT***Prostate CancerS \[241\]miR-519d***PTENAKT***Hepatocellular Carcinoma[@bib286]miR-520 b/c/e***EGFR, mTOR, SIRT1***Gastric Cancer, FibrosarcomaS \[242\], [@bib333]miR-532***KRAS, SIRT3***Lung Adenocarcinoma, Ovarian CancerS \[243\], [@bib449]miR-543***SIRT1***Hypertension, Gastric CancerS \[244,245\]miR-545***EGFR***Colorectal CancerS \[246\]miR-548i***AKT***Non-Small Cell Lung CancerS \[247\]miR-561***MYC***Gastric CancerS \[248\]miR-577***PTEN***Glioblastoma[@bib283]miR-579***MDM2***MelanomaS \[249\]miR-600***TP53***Colorectal CancerS \[250\]miR-601***SIRT1***Pancreatic CancerS \[251\]miR-606***MDM2***Breast Cancer, Lung Cancer, Colorectal Cancer[@bib353]miR-610***MDM2***GliomaS \[252\]miR-613***KRAS***Ovarian CancerS \[253\]miR-615***AKT***Pancreatic Ductal AdenocarcinomaS \[254\]miR-622***KRAS***Lung Cancer, Colorectal CancerS \[255,256\]miR-637***AKT***Glioma[@bib267]miR-638***AKT***Lung CancerS \[257\]miR-641***MDM2***Lung CancerS \[258\]miR-650***AKT***Rheumatoid ArthritisS \[259\]miR-660***MDM2***Lung Cancer[@bib354]miR-7***EGFR, mTOR***Ovarian Cancer, Glioblastoma, Lung Cancer, Breast Cancer, Hepatocellular Carcinoma, Gastric CancerS \[260,261\], [@bib277], [@bib278], [@bib279], [@bib329], [@bib330]miR-718***PTEN***Kaposi\'s Sarcoma, InflammationS \[262\], [@bib292]miR-744***MYC***Hepatocellular Carcinoma[@bib221]miR-758***mTOR, MDM2***Hepatocellular CarcinomaS \[263\]miR-766***MDM2, SIRT6***Breast Cancer, Dermal FibroblastS \[264\], [@bib421]miR-768***KRAS***Lung CancerS \[265\]miR-875***EGFR***Prostate CancerS \[266\]miR-9/a***SIRT1PTEN***Hepatic Stellate Cells, Non-Alcoholic Fatty Liver Disease, Acute Myeloid Leukemia, Colorectal Cancer, Nasopharyngeal Carcinoma, Non-Small Cell Lung CancerS \[267--272\]miR-92***TP53***Multiple Myeloma, Pluripotent Stem CellsS \[25,55\]miR-923***AKT***Lung CancerS \[257\]miR-93***MYC, PTEN, SIRT1***Colon Cancer, Ovarian Cancer, Myocardial Ischemia/Reperfusion(I/R) Injury, Breast Cancer, AgingS \[18,273,274\], [@bib290], [@bib412]miR-95***PTEN***Radioresistance Lung CancerS \[138\]miR-96***KRAS, mTOR***Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Colorectal Cancer, Myocardial HypertrophyS \[184,275--277\], [@bib206]miR-98***MYC, TP53***Breast Cancer, Lung CancerS \[5,222\]miR-99a/b***mTOR***Breast Cancer, Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrioid Endometrial Carcinoma[@bib324], [@bib325], [@bib327]

6. Towards future applications for disrupting cancer cell glycolysis {#sec6}
====================================================================

Metabolomics provides a new exciting platform to explore potential anti-cancer drugs. A universally observed phenotype of malignant cells is their propensity to import glucose and secrete lactate, even in the presence of oxygen. The characterization of aerobic glycolysis has led to dramatic advances in tumor imaging. Positron emission tomography (PET) scans, widely used for cancer diagnosis, exploit the ability of cancer cells to sequester excessive glucose from the blood stream. Ever since aerobic glycolysis was found to be a characteristic of tumor cells and was accepted as a hallmark of cancer, it has been proposed that suppressing aerobic glycolysis would be a promising strategy to treat cancer. As a consequence, several studies have reported the use of glycolytic enzyme inhibitors. For instance, lonidamine as a HK2 inhibitor, PEP analogues as PKM inhibitors, as well as FX-11 and panepoxydone as LDHA inhibitors, have been considered potential therapeutic agents (reviewed in [@bib451], [@bib452]). However, as glycolysis is also a vital metabolic pathway in normal cells, inhibition of aerobic glycolysis remains challenging when identifying potential cancer-specific targets. Although a definitive explanation for Warburg\'s observations is overdue, the control of this process by oncogenes and tumor suppressors, coupled with epigenetic factors including microRNAs, provides additional insight. So far, ample evidence supports associations between the metabolic shift in cancer cells and oncogene activation or inactivation of tumor suppressors. The elusive nature of metabolic rewiring and branching in cancer cells, along with influences upon other signaling pathways, raise concerns as to whether targeting a single component of this complex circuit will be sufficient to eradicate cancer cells with minimal side effects. Despite several reports of the involvement of miRNA-mediated gene regulation, there is still much to learn about how miRNAs contribute to the Warburg effect. Development of new miRNA-mediated strategies, that target metabolic pathways rather than single components, have the potential to enhance future cancer treatment. Systems biology approaches that iteratively couple massively parallel gene expression analytical technologies with high throughput functional screens, may identify additional miRNAs or miRNA-targets with promise for cancer diagnosis, prognosis and drug development. Polymorphisms in the miRNA binding sites of oncogenes are known to influence cancer predisposition and therapeutic response, which may further inform target selection [@bib198], [@bib453]. Conversely, acquired somatic mutations in miRNA-binding sites may also lead to the reduced efficacy of miRNA-based therapies. Similarly, the demands of other tissues, such as the highly glucose-dependent nature of brain and retina, will necessitate tissue-specific delivery of anti-glycolysis miRNAs in a therapeutic context where administration already presents challenges. Regardless, multi-faceted solutions are required to provide hope for cancer patients who currently have limited options.

7. Conclusion {#sec7}
=============

Aerobic glycolysis, a hallmark of cancer, is the consequence of specific driver mutations and re-equilibrated homeostasis in tumor cells. While cellular responses to the environment continue to involve the existing signaling pathways, longer adaptive responses invoke post-transcriptional and epigenetic control of gene expression. By regulating multiple cellular pathways and multiple components of individual pathways, microRNAs fine-tune expression to ensure high level buffering of adaptive responses. Thorough understanding of these regulatory processes should provide the capacity to suppress metabolism and inhibit cancer cell survival under stress. With the advent of RNA-based therapies and the development of drugs that modulate the activity of microRNA targets, or even microRNAs themselves, this review has highlighted metabolic processes that may be disrupted by novel therapeutic interventions
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